Search This Blog

Monday, July 1, 2024

Lpngboard Breakthrough Therapy Designation for Seizure Med

 -Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older.

https://www.businesswire.com/news/home/20240701243172/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.